| UPN | Age/sex | Duration (months) | DAS | Previous medication | Current medication* | ||||
| NSAIDs | MTX | PDN | DMARDs | Biologic | |||||
| 1 | 43/F | 6 | 7.1 | No | 15 mg/week | No | LEF | Infliximab† | MTX, Infliximab |
| 2 | 61/M | 36 | 5.3 | No | 20 mg/week | No | LEF, CSA, SSA | Etanercept‡, Adalimumab§ | MTX |
| 3 | 77/F | 3 | 7.6 | No | No | No | None | None | None |
| 4 | 58/M | 72 | 8.4 | No | 20 mg/week | No | LEF, SSA | Kineret¶ | Kineret |
| 5 | 71/M | 6 | 4.6 | No | 20 mg/week | No | None | Infliximab | Infliximab |
| 6 | 32/F | 3 | 5.1 | No | 15 mg/week | No | CSA, SSA, HCQ | None | MTX, HCQ, SSA |
| 7 | 77/F | 9 | 5.4 | No | 15 mg/week | 5 mg/day | LEF, CSA, SSA, D-Pen | None | LEF, PDN |
| 8 | 58/M | 15 | 3.8 | No | 20 mg/week | 7.5 mg/day | LEF, CSA, SSA, d-pen | Adalimumab | MTX, LEF, PDN |
| 9 | 73/F | 4 | 5.6 | No | 15 mg/week | No | LEF, CSA, SSA, HCQ | Infliximab, Adalimumab | MTX, Adalimumab |
| 10 | 56/F | 25 | 3.0 | No | 15 mg/week | 5 mg/day | CSA | None | MTX, PDN |
| 11 | 50/F | 32 | 7.1 | No | 15 mg/week | 5 mg/day | LEF, CSA, HCQ | Infliximab, Kineret, Rituximab** | LEF, Rituximab, PDN |
| 12 | 66/F | 240 | 6.1 | No | 15 mg/week | 5 mg/day | LEF, CSA | Adalimumab | Adalimumab, PDN |
| 13 | 54/F | 6 | 5.8 | Yes | 15 mg/week | No | HCQ | None | MTX, HHQ |
| 14 | 77/M | 60 | 2.6 | No | 20 mg/week | 5 mg/day | CSA | None | MTX, PDN |
| 15 | 75/F | 15 | 3.9 | No | 15 mg/week | No | LEF, CSA, SSA, HCQ, d-pen | Adalimumab | MTX, Adalimumab |
| 16 | 62/M | 156 | 5.8 | No | 20 mg/week | No | LEF, CSA | Infliximab, Rituximab | LEF, Rituximab |
| 17 | 53/M | 72 | 6.8 | No | 20 mg/week | No | LEF, CSA | Infliximab, Rituximab | LEF, MTX, CSA, Infliximab |
| 18 | 31/F | 12 | 2.2 | No | No | No | None | None | None |
| 19 | 58/M | 5 | 7.3 | No | No | No | None | None | None |
| 20 | 59/F | 48 | 8.4 | Yes | 15 mg/week | 5 mg/day | LEF, CSA, d-pen | None | LEF, CSA, PDN |
| 21 | 51/F | 240 | 6.5 | Yes | 15 mg/week | No | None | None | MTX |
| 22 | 77/F | 3 | 8.4 | No | No | No | None | None | None |
| 23 | 58/F | 60 | 6.8 | Yes | 15 mg/week | No | HCQ | None | HHQ, PDN |
| 24 | 54/M | 3 | 5.8 | No | No | No | None | None | None |
| 25 | 33/F | 6 | 2.6 | No | No | No | None | None | None |
| 26 | 45/F | 36 | 5.3 | No | 20 mg/week | 5 mg/day | CSA | None | MTX, HHQ |
*Patients had discontinued any medication for at least 24 h prior to BM aspiration. †Human/murine chimeric anti-TNFα monoclonal antibody (3 mg/kg every 4–8 weeks). ‡Recombinant human soluble p75 TNF receptor fusion protein (25 mg/biweekly). §Humanised anti-TNF monoclonal antibody (40 mg every 2 weeks). ¶Interleukin 1β receptor antagonist (100 mg/day). **Human/murine chimeric anti-CD20 monoclonal antibody (2 doses of 1 g within 2 weeks). CSA, ciclosporine-A (150 mg/day) ; d-pen, d-penicillamine (200 mg/day); DAS, Disease Activity Score; DMARDs, disease-modifying antirheumatic drugs; HCQ, hydroxychloroquine (400 mg/day); HHQ, hexahydroquinoline; LEF, leflunamide (10–20 mg/day); MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; PDN, prednisone; SSA, sulphasalazine-A (2 g/day); TNF, tumour necrosis factor; UPN, unique patient number.